Summit Operating Income from 2010 to 2024
SMMT Stock | USD 19.00 0.58 3.15% |
Operating Income | First Reported 2011-09-30 | Previous Quarter -44.8 M | Current Value -58.1 M | Quarterly Volatility 71.4 M |
Check Summit Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Summit Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 17.3 M or Selling General Administrative of 31.8 M, as well as many indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.0 or PTB Ratio of 19.78. Summit financial statements analysis is a perfect complement when working with Summit Therapeutics Valuation or Volatility modules.
Summit | Operating Income |
Latest Summit Therapeutics' Operating Income Growth Pattern
Below is the plot of the Operating Income of Summit Therapeutics PLC over the last few years. Operating Income is the amount of profit realized from Summit Therapeutics PLC operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Summit Therapeutics PLC is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Summit Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Summit Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Operating Income | 10 Years Trend |
|
Operating Income |
Timeline |
Summit Operating Income Regression Statistics
Arithmetic Mean | (31,944,821) | |
Coefficient Of Variation | (113.91) | |
Mean Deviation | 30,230,546 | |
Median | (19,151,725) | |
Standard Deviation | 36,388,585 | |
Sample Variance | 1324.1T | |
Range | 104.9M | |
R-Value | (0.75) | |
Mean Square Error | 629.9T | |
R-Squared | 0.56 | |
Significance | 0 | |
Slope | (6,079,435) | |
Total Sum of Squares | 18537.8T |
Summit Operating Income History
Other Fundumenentals of Summit Therapeutics PLC
Summit Therapeutics Operating Income component correlations
Click cells to compare fundamentals
About Summit Therapeutics Financial Statements
Summit Therapeutics shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Summit Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Summit Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Summit Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Operating Income | -89.7 M | -85.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.